Advances in pediatric gliomas: from molecular characterization to personalized treatments.
Molecular characterization
Pediatric gliomas
Targeted therapies
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
received:
01
01
2024
accepted:
21
03
2024
revised:
12
03
2024
medline:
1
4
2024
pubmed:
1
4
2024
entrez:
1
4
2024
Statut:
aheadofprint
Résumé
Pediatric gliomas, consisting of both pediatric low-grade (pLGG) and high-grade gliomas (pHGG), are the most frequently occurring brain tumors in children. Over the last decade, several milestone advancements in treatments have been achieved as a result of stronger understanding of the molecular biology behind these tumors. This review provides an overview of pLGG and pHGG highlighting their clinical presentation, molecular characteristics, and latest advancements in therapeutic treatments. Conclusion: The increasing understanding of the molecular biology characterizing pediatric low and high grade gliomas has revolutionized treatment options for these patients, especially in pLGG. The implementation of next generation sequencing techniques for these tumors is crucial in obtaining less toxic and more efficacious treatments. What is Known: • Pediatric Gliomas are the most common brain tumour in children. They are responsible for significant morbidity and mortality in this population. What is New: • Over the last two decades, there has been a significant increase in our global understanding of the molecular background of pediatric low and high grade gliomas. • The implementation of next generation sequencing techniques for these tumors is crucial in obtaining less toxic and more efficacious treatments, with the ultimate goal of improving both the survival and the quality of life of these patients.
Identifiants
pubmed: 38558313
doi: 10.1007/s00431-024-05540-4
pii: 10.1007/s00431-024-05540-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer Statistics, 2022. CA A Cancer J Clinicians 72(1):7–33. https://doi.org/10.3322/caac.21708
doi: 10.3322/caac.21708
Pollack IF, Agnihotri S, Broniscer A (2019) Childhood brain tumors: current management, biological insights, and future directions. J Neurosurg Pediatr 23(3):261–273. https://doi.org/10.3171/2018.10.PEDS18377
doi: 10.3171/2018.10.PEDS18377
pubmed: 30835699
pmcid: 6823600
Curtin SC, Minino AM, Anderson RN (2016) Declines in cancer death rates among children and adolescents in the United States, 1999–2014. NCHS Data Brief 257:1–8
Ostrom QT, de Blank PM, Kruchko C, Petersen CM, Liao P, Finlay JL, Stearns DS, Wolff JE, Wolinsky Y, Letterio JJ, Barnholtz-Sloan JS (2015) Alex’s Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 10):x1–x36. https://doi.org/10.1093/neuonc/nou327
doi: 10.1093/neuonc/nou327
pubmed: 25542864
Collins VP, Jones DT, Giannini C (2015) Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129(6):775–788. https://doi.org/10.1007/s00401-015-1410-7
doi: 10.1007/s00401-015-1410-7
pubmed: 25792358
pmcid: 4436848
Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D, Hawkins C, Ho CY, Hwang E, Jabado N, Kilburn LB, Lassaletta A, Ligon KL, Kieran M (2017) Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol 19(6):750–761. https://doi.org/10.1093/neuonc/now209
doi: 10.1093/neuonc/now209
pubmed: 27683733
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst M, Ellison D, Fangusaro J, Fisher MJ, Foreman N, Fouladi M, Hargrave D, Hawkins C, Jabado N, Massimino M, Mueller S, Perilongo G, Schouten van Meeteren AYN, Tabori U, Warren K, Packer RJ (2018) Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol 20(2):160–173. https://doi.org/10.1093/neuonc/nox141
doi: 10.1093/neuonc/nox141
pubmed: 29016845
Collins KL, Pollack IF (2020) Pediatric low-grade gliomas. Cancers 12(5):1152. https://doi.org/10.3390/cancers12051152
doi: 10.3390/cancers12051152
pubmed: 32375301
pmcid: 7281318
Shankar A, Bomanji J, Hyare H (2020) Hybrid PET-MRI imaging in paediatric and TYA brain tumours: clinical applications and challenges. J Pers Med 10(4):218. https://doi.org/10.3390/jpm10040218
doi: 10.3390/jpm10040218
pubmed: 33182433
pmcid: 7711629
Koob M, Girard N (2014) Cerebral tumors: specific features in children. Diagn Interv Imaging 95(10):965–983. https://doi.org/10.1016/j.diii.2014.06.017
doi: 10.1016/j.diii.2014.06.017
pubmed: 25150727
Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, Rusu A, Irimie A, Atanasov AG, Slaby O, Ionescu C, Berindan-Neagoe I (2019) A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers 11(10):1618. https://doi.org/10.3390/cancers11101618
doi: 10.3390/cancers11101618
pubmed: 31652660
pmcid: 6827047
Ryall S, Tabori U, Hawkins C (2020) Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 8(1):30. https://doi.org/10.1186/s40478-020-00902-z
doi: 10.1186/s40478-020-00902-z
pubmed: 32164789
pmcid: 7066826
Cacciotti C, Fleming A, Ramaswamy V (2020) Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy. J Pathol 251(3):249–261. https://doi.org/10.1002/path.5457
doi: 10.1002/path.5457
pubmed: 32391583
Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, Siddaway R, Li C, Pajovic S, Arnoldo A, Kowalski PE, Johnson M, Sheth J, Lassaletta A, Tatevossian RG, Orisme W, Qaddoumi I, Surrey LF, Li MM, Waanders AJ, Hawkins C (2020) Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 37(4):569-583.e5. https://doi.org/10.1016/j.ccell.2020.03.011
doi: 10.1016/j.ccell.2020.03.011
pubmed: 32289278
pmcid: 7169997
Jones DT, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, Collins VP (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Can Res 68(21):8673–8677. https://doi.org/10.1158/0008-5472.CAN-08-2097
doi: 10.1158/0008-5472.CAN-08-2097
Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Guerreiro Stucklin A, Zhukova N, Arnoldo A, Ryall S, Ling C, McKeown T, Loukides J, Cruz O, de Torres C, Ho CY, Packer RJ, Tatevossian R, Qaddoumi I, Harreld JH, Tabori U (2017) Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 35(25):2934–2941. https://doi.org/10.1200/JCO.2016.71.8726
doi: 10.1200/JCO.2016.71.8726
pubmed: 28727518
pmcid: 5791837
Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ (2017) Neurofibromatosis type 1. Nat Rev Dis Primers 3:17004. https://doi.org/10.1038/nrdp.2017.4
doi: 10.1038/nrdp.2017.4
pubmed: 28230061
Friedman, JM (1998) Neurofibromatosis 1. In M. P. Adam (Eds) et al. GeneReviews
Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL (2009) Neurofibromatosis type 1 revisited. Pediatr 123(1):124–133. https://doi.org/10.1542/peds.2007-3204
doi: 10.1542/peds.2007-3204
Hirbe AC, Gutmann DH (2014) Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 13(8):834–843. https://doi.org/10.1016/S1474-4422(14)70063-8
doi: 10.1016/S1474-4422(14)70063-8
pubmed: 25030515
Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM, Reilly KM, Stemmer-Rachamimov A, Stewart DR, Viskochil D, Widemann B, Perry A (2017) Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol 67:1–10. https://doi.org/10.1016/j.humpath.2017.05.010
doi: 10.1016/j.humpath.2017.05.010
pubmed: 28551330
pmcid: 5628119
Packer RJ, Iavarone A, Jones DTW, Blakeley JO, Bouffet E, Fisher MJ, Hwang E, Hawkins C, Kilburn L, MacDonald T, Pfister SM, Rood B, Rodriguez FJ, Tabori U, Ramaswamy V, Zhu Y, Fangusaro J, Johnston SA, Gutmann DH (2020) Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro Oncol 22(6):773–784. https://doi.org/10.1093/neuonc/noaa036
doi: 10.1093/neuonc/noaa036
pubmed: 32055852
pmcid: 7283027
Soleman J, Dvir R, Ben-Sira L, Yalon M, Boop F, Constantini S, Roth J (2021) MRI-based diagnosis and treatment of pediatric brain tumors: is tissue sample always needed? Child’s Nerv Syst 37(5):1449–1459. https://doi.org/10.1007/s00381-021-05148-1
doi: 10.1007/s00381-021-05148-1
Bale TA (2020) FGFR-gene family alterations in low-grade neuroepithelial tumors. Acta Neuropathol Commun 8(1):21. https://doi.org/10.1186/s40478-020-00898-6
doi: 10.1186/s40478-020-00898-6
pubmed: 32085805
pmcid: 7035775
Du Z, Lovly CM (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17(1):58. https://doi.org/10.1186/s12943-018-0782-4
doi: 10.1186/s12943-018-0782-4
pubmed: 29455648
pmcid: 5817791
Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2):116–129. https://doi.org/10.1038/nrc2780
doi: 10.1038/nrc2780
pubmed: 20094046
Tahiri Elousrouti L, Lamchahab M, Bougtoub N, Elfatemi H, Chbani L, Harmouch T, Maaroufi M, Amarti Riffi A (2016) Subependymal giant cell astrocytoma (SEGA): a case report and review of the literature. J Med Case Reports 10:35. https://doi.org/10.1186/s13256-016-0818-6
doi: 10.1186/s13256-016-0818-6
Jansen AC, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, D’Amato L, Beaure d’Augères G, de Vries PJ, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, Nabbout R, O’Callaghan F, Qin J, Kingswood JC (2019) Newly diagnosed and growing subependymal giant cell astrocytoma in adults with tuberous sclerosis complex: results from the International TOSCA Study. Front Neurol 10:821. https://doi.org/10.3389/fneur.2019.00821
doi: 10.3389/fneur.2019.00821
pubmed: 31428037
pmcid: 6688052
Bongaarts A, Giannikou K, Reinten RJ, Anink JJ, Mills JD, Jansen FE, Spliet GMW, den Dunnen WFA, Coras R, Blümcke I, Paulus W, Scholl T, Feucht M, Kotulska K, Jozwiak S, Buccoliero AM, Caporalini C, Giordano F, Genitori L, Söylemezoğlu F, Aronica E (2017) Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations. Oncotarget 8(56):95516–95529. https://doi.org/10.18632/oncotarget.20764
doi: 10.18632/oncotarget.20764
pubmed: 29221145
pmcid: 5707039
Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355(13):1345–1356. https://doi.org/10.1056/NEJMra055323
doi: 10.1056/NEJMra055323
pubmed: 17005952
Jóźwiak S, Nabbout R, Curatolo P, participants of the TSC Consensus Meeting for SEGA and Epilepsy Management (2013) Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): clinical recommendations. Euro J Paediatr Neuro 17(4):348–352. https://doi.org/10.1016/j.ejpn.2012.12.008
doi: 10.1016/j.ejpn.2012.12.008
Weidman DR, Pole JD, Bouffet E, Taylor MD, Bartels U (2015) Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). Pediatr Blood Cancer 62(10):1754–1760. https://doi.org/10.1002/pbc.25573
doi: 10.1002/pbc.25573
pubmed: 25929843
Luo C, Ye WR, Shi W, Yin P, Chen C, He YB, Chen MF, Zu XB, Cai Y (2022) Perfect match: mTOR inhibitors and tuberous sclerosis complex. Orphanet J Rare Dis 17(1):106. https://doi.org/10.1186/s13023-022-02266-0
doi: 10.1186/s13023-022-02266-0
pubmed: 35246210
pmcid: 8895788
Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Lyons-Weiler MA, LaFramboise WA, Burger PC, Brat DJ, Rosenblum MK, Holmes EJ, Zhou T, Jakacki RI, Children’s Oncology Group (2011) IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group. Child’s Nerv Syst 27(1):87–94. https://doi.org/10.1007/s00381-010-1264-1
doi: 10.1007/s00381-010-1264-1
Yeo KK, Alexandrescu S, Cotter JA, Vogelzang J, Bhave V, Li MM, Ji J, Benhamida JK, Rosenblum MK, Bale TA, Bouvier N, Kaneva K, Rosenberg T, Lim-Fat MJ, Ghosh H, Martinez M, Aguilera D, Smith A, Goldman S, Diamond EL, Wright KD (2023) Neuro Oncol 25(1):199–210. https://doi.org/10.1093/neuonc/noac132
doi: 10.1093/neuonc/noac132
pubmed: 35604410
Perret C, Boltshauser E, Scheer I, Kellenberger CJ, Grotzer MA (2011) Incidental findings of mass lesions on neuroimages in children. Neurosurg Focus 31(6):E20. https://doi.org/10.3171/2011.9.FOCUS11121
doi: 10.3171/2011.9.FOCUS11121
pubmed: 22133179
Winesett SP, Tuite GF, Jallo G, Carey C, Rodriguez LF, Stapleton S (2019) Incidentally found brain tumors in the pediatric population: a case series and proposed treatment algorithm. J Neuro Oncol 141(2):355–361. https://doi.org/10.1007/s11060-018-03039-1
doi: 10.1007/s11060-018-03039-1
de Blank P, Bandopadhayay P, Haas-Kogan D, Fouladi M, Fangusaro J (2019) Management of pediatric low-grade glioma. Curr Opin Pediatr 31(1):21–27. https://doi.org/10.1097/MOP.0000000000000717
doi: 10.1097/MOP.0000000000000717
pubmed: 30531227
pmcid: 6664811
Upadhyaya SA, Koschmann C, Muraszko K, Venneti S, Garton HJ, Hamstra DA, Maher CO, Betz BL, Brown NA, Wahl D, Weigelin HC, DuRoss KE, Leonard AS, Robertson PL (2017) Brainstem low-grade gliomas in children-excellent outcomes with multimodality therapy. J Child Neurol 32(2):194–203. https://doi.org/10.1177/0883073816675547
doi: 10.1177/0883073816675547
pubmed: 27810966
Bennett J, Erker C, Lafay-Cousin L, Ramaswamy V, Hukin J, Vanan MI, Cheng S, Coltin H, Fonseca A, Johnston D, Lo A, Zelcer S, Alvi S, Bowes L, Brossard J, Charlebois J, Eisenstat D, Felton K, Fleming A, Jabado N, Bartels U (2020) Canadian Pediatric Neuro-Oncology Standards of Practice. Front Oncol 10:593192
doi: 10.3389/fonc.2020.593192
pubmed: 33415075
pmcid: 7783450
Lassaletta A, Scheinemann K, Zelcer SM, Hukin J, Wilson BA, Jabado N, Carret AS, Lafay-Cousin L, Larouche V, Hawkins CE, Pond GR, Poskitt K, Keene D, Johnston DL, Eisenstat DD, Krishnatry R, Mistry M, Arnoldo A, Ramaswamy V, Huang A, Bouffet E (2016) Phase II weekly vinblastine for chemotherapy-naïve children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium Study. J Clin Oncol 34(29):3537–3543. https://doi.org/10.1200/JCO.2016.68.1585
doi: 10.1200/JCO.2016.68.1585
pubmed: 27573663
Krishnatry R, Zhukova N, Guerreiro Stucklin AS, Pole JD, Mistry M, Fried I, Ramaswamy V, Bartels U, Huang A, Laperriere N, Dirks P, Nathan PC, Greenberg M, Malkin D, Hawkins C, Bandopadhayay P, Kieran MW, Manley PE, Bouffet E, Tabori U (2016) Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer 122(8):1261–1269. https://doi.org/10.1002/cncr.29907
doi: 10.1002/cncr.29907
pubmed: 26970559
Perreault S, Larouche V, Tabori U, Hawkin C, Lippé S, Ellezam B, Décarie JC, Théoret Y, Métras MÉ, Sultan S, Cantin É, Routhier MÈ, Caru M, Legault G, Bouffet É, Lafay-Cousin L, Hukin J, Erker C, Jabado N (2019) A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer 19(1):1250. https://doi.org/10.1186/s12885-019-6442-2
doi: 10.1186/s12885-019-6442-2
pubmed: 31881853
pmcid: 6935133
Selt F, van Tilburg CM, Bison B, Sievers P, Harting I, Ecker J, Pajtler KW, Sahm F, Bahr A, Simon M, Jones DTW, Well L, Mautner VF, Capper D, Hernáiz Driever P, Gnekow A, Pfister SM, Witt O, Milde T (2020) Response to trametinib treatment in progressive pediatric low-grade glioma patients. J Neuro Oncol 149(3):499–510. https://doi.org/10.1007/s11060-020-03640-3
doi: 10.1007/s11060-020-03640-3
Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick MC, Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina O, Heisey K, Clapp DW, Zhang C, Widemann BC (2020) Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 382(15):1430–1442. https://doi.org/10.1056/NEJMoa1912735
doi: 10.1056/NEJMoa1912735
pubmed: 32187457
pmcid: 7305659
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Fouladi M (2019) Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 20(7):1011–1022. https://doi.org/10.1016/S1470-2045(19)30277-3
doi: 10.1016/S1470-2045(19)30277-3
pubmed: 31151904
pmcid: 6628202
Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, Campagne O, Banerjee A, Gururangan S, Kilburn LB, Goldman S, Qaddoumi I, Baxter P, Vezina G, Bregman C, Patay Z, Jones JY, Stewart CF, Fisher MJ, Doyle LA, Fouladi M (2021) A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro Oncol 23(10):1777–1788. https://doi.org/10.1093/neuonc/noab047
doi: 10.1093/neuonc/noab047
pubmed: 33631016
pmcid: 8485450
Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, Geoerger B, Hingorani P, Dunkel IJ, Russo MW, Tseng L, Dasgupta K, Gasal E, Whitlock JA, Kieran MW (2019) Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I/IIa study. Clin Cancer Res 25(24):7303–7311. https://doi.org/10.1158/1078-0432.CCR-19-2177
doi: 10.1158/1078-0432.CCR-19-2177
pubmed: 31811016
Kieran MW, Geoerger B, Dunkel IJ, Broniscer A, Hargrave D, Hingorani P, Aerts I, Bertozzi AI, Cohen KJ, Hummel TR, Shen V, Bouffet E, Pratilas CA, Pearson ADJ, Tseng L, Nebot N, Green S, Russo MW, Whitlock JA (2019) A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors. Clin Cancer Res 25(24):7294–7302. https://doi.org/10.1158/1078-0432.CCR-17-3572
doi: 10.1158/1078-0432.CCR-17-3572
pubmed: 31506385
Bouffet E, Hansford JR, Garrè ML, Hara J, Plant-Fox A, Aerts I, Locatelli F, van der Lugt J, Papusha L, Sahm F, Tabori U, Cohen KJ, Packer RJ, Witt O, Sandalic L, Pereira B, da Silva A, Russo M, Hargrave DR (2023) Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 389(12):1108–1120. https://doi.org/10.1056/NEJMoa2303815
doi: 10.1056/NEJMoa2303815
pubmed: 37733309
Nobre L, Zapotocky M, Ramaswamy V, Ryall S, Bennett J, Alderete D, Balaguer Guill J, Baroni L, Bartels U, Bavle A, Bornhorst M, Boue DR, Canete A, Chintagumpala M, Coven SL, Cruz O, Dahiya S, Dirks P, Dunkel IJ, Eisenstat D, Tabori U (2020) Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis Oncol 4:PO.19.00298. https://doi.org/10.1200/PO.19.00298
doi: 10.1200/PO.19.00298
pubmed: 32923898
pmcid: 7446502
Dai S, Zhou Z, Chen Z, Xu G, Chen Y (2019) Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors. Cells 8(6):614. https://doi.org/10.3390/cells8060614
doi: 10.3390/cells8060614
pubmed: 31216761
pmcid: 6627960
Farouk Sait S, Gilheeney SW, Bale TA, Haque S, Dinkin MJ, Vitolano S, Rosenblum MK, Ibanez K, Prince DE, Spatz KH, Dunkel IJ, Karajannis MA (2021) Debio1347, an oral FGFR inhibitor: results from a single-center study in pediatric patients with recurrent or refractory FGFR-altered gliomas. JCO Precis Oncol 5:PO.20.00444. https://doi.org/10.1200/PO.20.00444
doi: 10.1200/PO.20.00444
pubmed: 34250399
pmcid: 8232545
Kilburn LB, Khuong-Quang DA, Hansford JR, Landi D, van der Lugt J, Leary SES, Driever PH, Bailey S, Perreault S, McCowage G, Waanders AJ, Ziegler DS, Witt O, Baxter PA, Kang HJ, Hassall TE, Han JW, Hargrave D, Franson AT, Yalon Oren M, Nysom K (2023) The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. https://doi.org/10.1038/s41591-023-02668-y
doi: 10.1038/s41591-023-02668-y
pubmed: 37978284
pmcid: 10803270
Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I, Kachurak K, Nan L, Kang KD, Totsch S, Schlappi C, Martin AM, Pastakia D, McNall-Knapp R, Farouk Sait S, Khakoo Y, Karajannis MA, Woodling K, Palmer JD, Osorio DS, Gillespie GY (2021) Oncolytic HSV-1 G207 Immunovirotherapy for pediatric high-grade gliomas. N Engl J Med 384(17):1613–1622. https://doi.org/10.1056/NEJMoa2024947
doi: 10.1056/NEJMoa2024947
pubmed: 33838625
pmcid: 8284840
Liu S, Zhao Q, Shi W, Zheng Z, Liu Z, Meng L, Dong L, Jiang X (2021) Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields. J Cancer 12(4):1094–1104. https://doi.org/10.7150/jca.51107
doi: 10.7150/jca.51107
pubmed: 33442407
pmcid: 7797642
Jones C, Perryman L, Hargrave D (2012) Paediatric and adult malignant glioma: close relatives or distant cousins? Nat Rev Clin Oncol 9(7):400–413. https://doi.org/10.1038/nrclinonc.2012.87
doi: 10.1038/nrclinonc.2012.87
pubmed: 22641364
Wang J, Huang TY, Hou Y, Bartom E, Lu X, Shilatifard A, Yue F, Saratsis A (2021) Epigenomic landscape and 3D genome structure in pediatric high-grade glioma. Sci Adv 7(23):eabg4126. https://doi.org/10.1126/sciadv.abg4126
doi: 10.1126/sciadv.abg4126
pubmed: 34078608
pmcid: 10166578
Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D, Peterson L, Camelo-Piragua S, Jones C, Mody R, Lowenstein PR, Castro MG (2016) Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget 7(40):65696–65706. https://doi.org/10.18632/oncotarget.11602
doi: 10.18632/oncotarget.11602
pubmed: 27582545
pmcid: 5323185
Jones C, Baker SJ (2014) Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer. https://doi.org/10.1038/nrc3811
doi: 10.1038/nrc3811
pubmed: 25230881
pmcid: 4747023
Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M, Stavropoulos J, Alon N, Pole JD, Ray PN, Navickiene V, Mangerel J, Remke M, Buczkowicz P, Ramaswamy V, Guerreiro Stucklin A, Li M, Young EJ, Zhang C, Castelo-Branco P, Tabori U (2015) BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 33(9):1015–1022. https://doi.org/10.1200/JCO.2014.58.3922
doi: 10.1200/JCO.2014.58.3922
pubmed: 25667294
pmcid: 4356711
Guerreiro Stucklin AS, Ryall S, Fukuoka K, Zapotocky M, Lassaletta A, Li C, Bridge T, Kim B, Arnoldo A, Kowalski PE, Zhong Y, Johnson M, Li C, Ramani AK, Siddaway R, Nobre LF, de Antonellis P, Dunham C, Cheng S, Boué DR, Hawkins C (2019) Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun 10(1):4343. https://doi.org/10.1038/s41467-019-12187-5
doi: 10.1038/s41467-019-12187-5
pubmed: 31554817
pmcid: 6761184
Braunstein S, Raleigh D, Bindra R, Mueller S, Haas-Kogan D (2017) Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J Neurooncol 134(3):541–549. https://doi.org/10.1007/s11060-017-2393-0
doi: 10.1007/s11060-017-2393-0
pubmed: 28357536
Reulecke BC, Erker CG, Fiedler BJ, Niederstadt TU, Kurlemann G (2008) Brain tumors in children: initial symptoms and their influence on the time span between symptom onset and diagnosis. J Child Neurol 23(2):178–183. https://doi.org/10.1177/0883073807308692
doi: 10.1177/0883073807308692
pubmed: 18160552
Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, Bjerke L, Clarke M, Vinci M, Nandhabalan M, Temelso S, Popov S, Molinari V, Raman P, Waanders AJ, Han HJ, Gupta S, Marshall L, Zacharoulis S, Vaidya S, Jones C (2017) Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32(4):520-537.e5. https://doi.org/10.1016/j.ccell.2017.08.017
doi: 10.1016/j.ccell.2017.08.017
pubmed: 28966033
pmcid: 5637314
Bechet D, Gielen GG, Korshunov A, Pfister SM, Rousso C, Faury D, Fiset PO, Benlimane N, Lewis PW, Lu C, David Allis C, Kieran MW, Ligon KL, Pietsch T, Ellezam B, Albrecht S, Jabado N (2014) Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol 128(5):733–741. https://doi.org/10.1007/s00401-014-1337-4
doi: 10.1007/s00401-014-1337-4
pubmed: 25200321
pmcid: 4201745
Cohen KJ, Jabado N, Grill J (2017) Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope? Neuro Oncol 19(8):1025–1034. https://doi.org/10.1093/neuonc/nox021
doi: 10.1093/neuonc/nox021
pubmed: 28371920
pmcid: 5570259
Buccoliero AM, Giunti L, Moscardi S, Castiglione F, Provenzano A, Sardi I, Scagnet M, Genitori L, Caporalini C (2022) Pediatric high grade glioma classification criteria and molecular features of a case series. Genes 13(4):624. https://doi.org/10.3390/genes13040624
doi: 10.3390/genes13040624
pubmed: 35456430
pmcid: 9028123
Baker SJ, Ellison DW, Gutmann DH (2016) Pediatric gliomas as neurodevelopmental disorders. Glia 64(6):879–895. https://doi.org/10.1002/glia.22945
doi: 10.1002/glia.22945
pubmed: 26638183
Gouda MA, Subbiah V (2023) Expanding the benefit: dabrafenib/trametinib as tissue-agnostic therapy for BRAF V600E-positive adult and pediatric solid tumors. Am Soc Clin Oncol Educ Book. Annual Meeting 43:e404770. https://doi.org/10.1200/EDBK_404770
doi: 10.1200/EDBK_404770
Rallis KS, George AM, Wozniak AM, Bigogno CM, Chow B, Hanrahan JG, Sideris M (2022) Molecular genetics and targeted therapies for paediatric high-grade glioma. Cancer Genom Proteomics 19(4):390–414. https://doi.org/10.21873/cgp.20328
doi: 10.21873/cgp.20328
Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stávale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C (2009) EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res 15(18):5753–5761. https://doi.org/10.1158/1078-0432.CCR-08-3210
doi: 10.1158/1078-0432.CCR-08-3210
pubmed: 19737945
Cheng F, Guo D (2019) MET in glioma: signaling pathways and targeted therapies. Journal of experimental & clinical cancer research : CR 38(1):270. https://doi.org/10.1186/s13046-019-1269-x
doi: 10.1186/s13046-019-1269-x
pmcid: 6585013
Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B, Sa JK, Cho HJ, Her NG, Zhang C, Zhao Z, Zhang Y, Zeng F, Wu F, Kang X, Liu Y, Jiang T (2018) Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell 175(6):1665-1678.e18. https://doi.org/10.1016/j.cell.2018.09.038
doi: 10.1016/j.cell.2018.09.038
pubmed: 30343896
Rosenberg T, Yeo KK, Mauguen A, Alexandrescu S, Prabhu SP, Tsai JW, Malinowski S, Joshirao M, Parikh K, Farouk Sait S, Rosenblum MK, Benhamida JK, Michaiel G, Tran HN, Dahiya S, Kachurak K, Friedman GK, Krystal JI, Huang MA, Margol AS, Karajannis MA (2022) Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. Neuro Oncol 24(11):1964–1975. https://doi.org/10.1093/neuonc/noac096
doi: 10.1093/neuonc/noac096
pubmed: 35397478
pmcid: 9629451
Hargrave DR, Terashima K, Hara J, Kordes UR, Upadhyaya SA, Sahm F, Bouffet E, Packer RJ, Witt O, Sandalic L, Kieloch A, Russo M, Cohen KJ, Investigators involved in the high-grade glioma cohort, (2023) Phase II trial of dabrafenib plus trametinib in relapsed/refractory BRAF V600-mutant pediatric high-grade glioma. J Clinical Oncol 41(33):5174–5183. https://doi.org/10.1200/JCO.23.00558
doi: 10.1200/JCO.23.00558
Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, Mehta MP (2019) First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. J Neurosurg Pediatr 23(6):719–725. https://doi.org/10.3171/2019.2.PEDS18480
doi: 10.3171/2019.2.PEDS18480
pubmed: 30952114
Gardner SL, Tarapore RS, Allen J, McGovern SL, Zaky W, Odia Y, Daghistani D, Diaz Z, Hall MD, Khatib Z, Koschmann C, Cantor E, Kurokawa R, MacDonald TJ, Aguilera D, Vitanza NA, Mueller S, Kline C, Lu G, Allen JE, Khatua S (2022) Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy. Neuro Oncol Adv 4(1):vdac143. https://doi.org/10.1093/noajnl/vdac143
doi: 10.1093/noajnl/vdac143
Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, Mehta MP (2019) Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neuro Oncol 145(1):97–105. https://doi.org/10.1007/s11060-019-03271-3
doi: 10.1007/s11060-019-03271-3
Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, Butowski NA, Sumrall A, Shonka N, Harrison RA, de Groot J, Koschmann C (2023) Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways. Cancer Discov 13(11):2370–2393. https://doi.org/10.1158/2159-8290.CD-23-0131
doi: 10.1158/2159-8290.CD-23-0131
pubmed: 37584601
pmcid: 10618742
Himes BT, Zhang L, Daniels DJ (2019) Treatment strategies in diffuse midline gliomas with the H3K27M mutation: the role of convection-enhanced delivery in overcoming anatomic challenges. Front Oncol 9:31. https://doi.org/10.3389/fonc.2019.00031
doi: 10.3389/fonc.2019.00031
pubmed: 30800634
pmcid: 6375835
Tejada S, Aquilina K, Goodden J, Pettorini B, Mallucci C, van Veelen ML, Thomale UW (2020) Biopsy in diffuse pontine gliomas: expert neurosurgeon opinion-a survey from the SIOPE brain tumor group. Child’s Nerv Syst 36(4):705–711. https://doi.org/10.1007/s00381-020-04523-8
doi: 10.1007/s00381-020-04523-8
Lassman AB, Sepúlveda-Sánchez JM, Cloughesy TF, Gil-Gil MJ, Puduvalli VK, Raizer JJ, De Vos FYF, Wen PY, Butowski NA, Clement PMJ, Groves MD, Belda-Iniesta C, Giglio P, Soifer HS, Rowsey S, Xu C, Avogadri F, Wei G, Moran S, Roth P (2022) Infigratinib in patients with recurrent gliomas and FGFR alterations: a multicenter phase II study. Clin Cancer Res 28(11):2270–2277. https://doi.org/10.1158/1078-0432.CCR-21-2664
doi: 10.1158/1078-0432.CCR-21-2664
pubmed: 35344029
pmcid: 9167702
Zarei M, Hue JJ, Hajihassani O, Graor HJ, Katayama ES, Loftus AW, Bajor D, Rothermel LD, Vaziri-Gohar A, Winter JM (2022) Clinical development of IDH1 inhibitors for cancer therapy. Cancer Treat Rev 103:102334. https://doi.org/10.1016/j.ctrv.2021.102334
doi: 10.1016/j.ctrv.2021.102334
pubmed: 34974243
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Trial Investigators INDIGO (2023) Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med 389(7):589–601. https://doi.org/10.1056/NEJMoa2304194
doi: 10.1056/NEJMoa2304194
pubmed: 37272516
Karajannis M, Onar-Thomas A, Baxter P, Butingan N, Fuller C, Gajjar A, Haque S, Jabado N, Lin T, Lucas J, MacDonald S, Matsushima C, Patel N, Pierson C, Springer L, Stark E, Souweidane M, Walsh M, Zaky W, Fouladi M, Cohen K (2022) HGG-06. Phase 2 study of veliparib and local irradiation, followed by maintenance veliparib and temozolomide, in patients with newly diagnosed high-grade glioma without H3 K27M or BRAF mutations: a report from the Children’s Oncology Group ACNS1721 Study. Neuro Oncol 24(Suppl 1):i60–i61. https://doi.org/10.1093/neuonc/noac079.222
doi: 10.1093/neuonc/noac079.222
pmcid: 9164928
Chan CY, Tan KV, Cornelissen B (2021) PARP inhibitors in cancer diagnosis and therapy. Clin Cancer Res 27(6):1585–1594. https://doi.org/10.1158/1078-0432.CCR-20-2766
doi: 10.1158/1078-0432.CCR-20-2766
pubmed: 33082213
International Cancer Genome Consortium PedBrain Tumor Project (2016) Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med 22(11):1314–1320. https://doi.org/10.1038/nm.4204
doi: 10.1038/nm.4204
Foster JH, Voss SD, Hall DC, Minard CG, Balis FM, Wilner K, Berg SL, Fox E, Adamson PC, Blaney SM, Weigel BJ, Mossé YP (2021) Activity of crizotinib in patients with ALK-aberrant relapsed/refractory neuroblastoma: a Children’s Oncology Group Study (ADVL0912). Clin Cancer Res 27(13):3543–3548. https://doi.org/10.1158/1078-0432.CCR-20-4224
doi: 10.1158/1078-0432.CCR-20-4224
pubmed: 33568345
pmcid: 8254744
Broniscer A, Jia S, Mandrell B, Hamideh D, Huang J, Onar-Thomas A, Gajjar A, Raimondi SC, Tatevossian RG, Stewart CF (2018) Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. Pediatr Blood Cancer 65(7):e27035. https://doi.org/10.1002/pbc.27035
doi: 10.1002/pbc.27035
pubmed: 29512900
pmcid: 5980705
Palmer JD, Tsang DS, Tinkle CL, Olch AJ, Kremer LCM, Ronckers CM, Gibbs IC, Constine LS (2021) Late effects of radiation therapy in pediatric patients and survivorship. Pediatr Blood Cancer 68(Suppl 2):e28349. https://doi.org/10.1002/pbc.28349
doi: 10.1002/pbc.28349
pubmed: 33818893
Duffner PK, Horowitz ME, Krischer JP, Burger PC, Cohen ME, Sanford RA, Friedman HS, Kun LE (1999) The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol 1(2):152–161. https://doi.org/10.1093/neuonc/1.2.152
doi: 10.1093/neuonc/1.2.152
pubmed: 11554387
pmcid: 1920752
Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS (2018) Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 19(5):705–714. https://doi.org/10.1016/S1470-2045(18)30119-0
doi: 10.1016/S1470-2045(18)30119-0
pubmed: 29606586
pmcid: 5949072
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Hyman DM (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378(8):731–739. https://doi.org/10.1056/NEJMoa1714448
doi: 10.1056/NEJMoa1714448
pubmed: 29466156
pmcid: 5857389
Doz F, van Tilburg CM, Geoerger B, Højgaard M, Øra I, Boni V, Capra M, Chisholm J, Chung HC, DuBois SG, Gallego-Melcon S, Gerber NU, Goto H, Grilley-Olson JE, Hansford JR, Hong DS, Italiano A, Kang HJ, Nysom K, Thorwarth A, Perreault S (2022) Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol 24(6):997–1007. https://doi.org/10.1093/neuonc/noab274
doi: 10.1093/neuonc/noab274
pubmed: 34850167
Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Fox E (2022) Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol 24(10):1776–1789. https://doi.org/10.1093/neuonc/noac087
doi: 10.1093/neuonc/noac087
pubmed: 35395680
pmcid: 9527518
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, De Braud FG (2017) Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372–001 and STARTRK-1). Cancer Discov 7(4):400–409. https://doi.org/10.1158/2159-8290.CD-16-1237
doi: 10.1158/2159-8290.CD-16-1237
pubmed: 28183697
pmcid: 5380583
Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20(11):651–668. https://doi.org/10.1038/s41577-020-0306-5
doi: 10.1038/s41577-020-0306-5
pubmed: 32433532
pmcid: 7238960
Xu S, Tang L, Li X, Fan F, Liu Z (2020) Immunotherapy for glioma: current management and future application. Cancer Lett 476:1–12. https://doi.org/10.1016/j.canlet.2020.02.002
doi: 10.1016/j.canlet.2020.02.002
pubmed: 32044356
Sener U, Ruff MW, Campian JL (2022) Immunotherapy in glioblastoma: current approaches and future perspectives. Int J Mol Sci 23(13):7046. https://doi.org/10.3390/ijms23137046
doi: 10.3390/ijms23137046
pubmed: 35806051
pmcid: 9266573
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Diaz LA Jr (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Sci (New York, N.Y.) 357(6349):409–413. https://doi.org/10.1126/science.aan6733
doi: 10.1126/science.aan6733
Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, Zhukova N, Mason G, Farah R, Afzal S, Yalon M, Rechavi G, Magimairajan V, Walsh MF, Constantini S, Dvir R, Tabori U (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34(19):2206–2211. https://doi.org/10.1200/JCO.2016.66.6552
doi: 10.1200/JCO.2016.66.6552
AlHarbi M, Ali Mobark N, AlMubarak L, Aljelaify R, AlSaeed M, Almutairi A, Alqubaishi F, Hussain ME, Balbaid AAO, Said Marie A, AlSubaie L, AlShieban S, alTassan, N., Ramkissoon, S. H., & Abedalthagafi, M. (2018) Durable response to nivolumab in a pediatric patient with refractory glioblastoma and constitutional biallelic mismatch repair deficiency. Oncologist 23(12):1401–1406. https://doi.org/10.1634/theoncologist.2018-0163
doi: 10.1634/theoncologist.2018-0163
pubmed: 30104292
pmcid: 6292541
Rittberg R, Harlos C, Rothenmund H, Das A, Tabori U, Sinha N, Singh H, Chodirker B, Kim CA (2021) Immune checkpoint inhibition as primary adjuvant therapy for an IDH1-mutant anaplastic astrocytoma in a patient with CMMRD: a case report-usage of immune checkpoint inhibition in CMMRD. Current Oncol (Toronto, Ont.) 28(1):757–766. https://doi.org/10.3390/curroncol28010074
doi: 10.3390/curroncol28010074
Westdorp H, Kolders S, Hoogerbrugge N, de Vries IJM, Jongmans MCJ, Schreibelt G (2017) Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. Cancer Lett 403:159–164. https://doi.org/10.1016/j.canlet.2017.06.018
doi: 10.1016/j.canlet.2017.06.018
pubmed: 28645564
Kim K, Kim HS, Kim JY, Jung H, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH, Choi JK (2020) Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. Nat Commun 11(1):951. https://doi.org/10.1038/s41467-020-14562-z
doi: 10.1038/s41467-020-14562-z
pubmed: 32075964
pmcid: 7031381
Zhang Z, Lu M, Qin Y, Gao W, Tao L, Su W, Zhong J (2021) Neoantigen: a new breakthrough in tumor immunotherapy. Front Immunol 12:672356. https://doi.org/10.3389/fimmu.2021.672356
doi: 10.3389/fimmu.2021.672356
pubmed: 33936118
pmcid: 8085349